和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

未开盘 05-06 16:00:00 EDT

19.82

+0.67

+3.50%

盘后19.55

-0.27-1.36%

19:26 EDT

最高19.98	最低19.59	成交量20.49万
今开19.87	昨收19.15	日振幅2.04%
总市值33.84亿	流通市值19.87亿	总股本1.71亿
成交额405.70万	换手率0.20%	流通股本1.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":19.82,"timestamp":1715025600000,"preClose":19.15,"halted":0,"volume":204876,"hourTrading":{"tag":"盘后","latestPrice":19.55,"preClose":19.82,"latestTime":"19:26 EDT","volume":3228,"amount":63287.48,"timestamp":1715038005838},"delay":0,"floatShares":100245329,"shares":170728717,"eps":0.59306,"marketStatus":"未开盘","marketStatusCode":0,"change":0.67,"latestTime":"05-06 16:00:00 EDT","open":19.87,"high":19.98,"low":19.59,"amount":4056998.8052160004,"amplitude":0.020366,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.59306,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1715068800000},"adr":1,"listingDate":1458187200000,"adjPreClose":19.15,"adrRate":5,"preHourTrading":{"tag":"盘前","latestPrice":19.62,"preClose":19.15,"latestTime":"08:41 EDT","volume":1316,"amount":25817.599892000002,"timestamp":1714999270311},"postHourTrading":{"tag":"盘后","latestPrice":19.55,"preClose":19.82,"latestTime":"19:26 EDT","volume":3228,"amount":63287.48,"timestamp":1715038005838},"volumeRatio":1.633264},"requestUrl":"/m/hq/s/HCM/wiki","defaultTab":"wiki","newsList":[{"id":"2433462261","title":"Paycor HCM Inc    预计每股收益 20 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433462261","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433462261?lang=zh_cn&edition=full","pubTime":"2024-05-07 09:44","pubTimestamp":1715046251,"startTime":"0","endTime":"0","summary":"   * Paycor HCM Inc     将于5月8日公布截至2024年3月31日的季度财报，预计该公司的季度收入将有所增长。* LSEG 分析师对 Paycor HCM 公司的平均预期为每股收益 20 美分。* 华尔街对 Paycor HCM Inc 的 12 个月目标价中位数为 23.00 美元，高于其上次收盘价 17.84 美元。5月7日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432658175","title":"Trinet Group, Inc.跌3.20% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2432658175","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432658175?lang=zh_cn&edition=full","pubTime":"2024-05-01 03:50","pubTimestamp":1714506652,"startTime":"0","endTime":"0","summary":"北京时间2024年05月01日03时50分，Trinet Group, Inc.股票出现波动，股价大幅下跌3.20%。Trinet Group, Inc.股票所在的人员配备服务行业中，整体跌幅为0.44%。其相关个股中，Staffing 360 Solutions, Inc.、Recruiter.Com Group, Inc.、Mastech Digital, Inc涨幅较大，罗致恒富、BOSS直聘、Insperity, Inc.较为活跃，换手率分别为1.31%、0.99%、0.81%，振幅较大的相关个股有Professional Diversity Network, Inc.、Recruiter.Com Group, Inc.、K力，振幅分别为16.21%、14.47%、8.41%。Trinet Group, Inc.公司简介：Trinet Group Inc通过专业雇主组织，为中小型企业提供外包薪资和人力资本管理解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240501035053861ea7d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240501035053861ea7d1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431557397","title":"迈凡妥靶向治疗，重塑梗阻性肥厚型心肌病管理新标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2431557397","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431557397?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:24","pubTimestamp":1714469040,"startTime":"0","endTime":"0","summary":"迈凡妥的获批，打破了肥厚型心肌病几十年来的治疗困局，为中国梗阻性肥厚型心肌病患者带来全新治疗选择。作为全球首创的心肌肌球蛋白抑制剂，迈凡妥可靶向疾病核心病理生理机制，通过与心肌肌球蛋白的可逆性结合，减少肌球蛋白和肌动蛋白横桥的数量，以减轻心肌的过度收缩，并改善舒张功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-04-30/doc-inatrcht1926845.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-04-30/doc-inatrcht1926845.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431510603","title":"全球首创心肌肌球蛋白抑制剂迈凡妥®（玛伐凯泰胶囊）在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431510603","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431510603?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:04","pubTimestamp":1714457040,"startTime":"0","endTime":"0","summary":"作为全球首创的心肌肌球蛋白抑制剂，迈凡妥可靶向疾病核心病理生理机制，通过与心肌肌球蛋白的可逆性结合，减少肌球蛋白和肌动蛋白横桥的数量，以减轻心肌的过度收缩，并改善舒张功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4401067_ZH01067_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431337239","title":"全球首创心肌肌球蛋白抑制剂迈凡妥在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431337239","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2431337239?lang=zh_cn&edition=full","pubTime":"2024-04-30 12:12","pubTimestamp":1714450352,"startTime":"0","endTime":"0","summary":"每经AI快讯，据百时美施贵宝中国官微消息，百时美施贵宝今日宣布，全球首创心肌肌球蛋白抑制剂迈凡妥?（通用名：玛伐凯泰胶囊）获中国国家药品监督管理局（NMPA）优先审评批准，用于治疗纽约心脏协会（NYHA）心功能分级II-III级的梗阻性肥厚型心肌病（HCM）成人患者，以改善运动能力和症状。这是全球首个也是目前唯一获批的心肌肌球蛋白抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404303065382974.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404303065382974.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431671864","title":"和黄医药(US ADR)上涨4.9%，报19.05美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431671864","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431671864?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:14","pubTimestamp":1714400057,"startTime":"0","endTime":"0","summary":"4月29日，和黄医药(US ADR)(HCM)盘中上涨4.9%，截至22:14，报19.05美元/股，成交166.19万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：5月22日，和黄医药(US ADR)将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/29221440477714.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431869847","title":"和黄医药盘中异动 股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431869847","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431869847?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:32","pubTimestamp":1714397540,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日21时32分，和黄医药股票出现异动，股价大幅拉升5.45%。截至发稿，该股报19.15美元/股，成交量8264股，换手率0.00%，振幅1.17%。和黄医药股票所在的制药行业中，整体涨幅为0.41%。其相关个股中，Deciphera Pharmaceuticals, Inc.、Phibro Animal Health Corporation、Akanda Corp.涨幅较大，Akanda Corp.、Sunshine Biopharma Inc.、Deciphera Pharmaceuticals, Inc.较为活跃，换手率分别为226.55%、104.26%、33.19%，振幅较大的相关个股有Phibro Animal Health Corporation、Sunshine Biopharma Inc.、Clever Leaves Holdings Inc C/Wts 18/12/2025，振幅分别为10.37%、9.36%、9.20%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042921322087bf9acd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042921322087bf9acd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431040747","title":"和黄医药(00013)上涨5.11%，报31.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431040747","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431040747?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:19","pubTimestamp":1714357155,"startTime":"0","endTime":"0","summary":"4月29日，和黄医药(00013)盘中上涨5.11%，截至10:19，报31.9元/股，成交3450.93万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29101940459601.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430065498","title":"和黄医药(00013.HK)合作伙伴武田创新药呋喹替尼获CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2430065498","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430065498?lang=zh_cn&edition=full","pubTime":"2024-04-28 22:54","pubTimestamp":1714316040,"startTime":"0","endTime":"0","summary":"和黄医药公布，合作伙伴武田取得欧洲药品管理局“EMA”人用药品委员会“CHMP”建议批准呋喹替尼用于治疗经治的成人转移性结直肠癌患者。欧盟委员会 在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时，将会把CHMP的积极意见纳入考量。倘获批，呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体“VEGFR”的选择性抑制剂。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345625/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430052492","title":"和黄医药(US ADR)下跌5.21%，报18.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430052492","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430052492?lang=zh_cn&edition=full","pubTime":"2024-04-26 22:20","pubTimestamp":1714141252,"startTime":"0","endTime":"0","summary":"4月26日，和黄医药(US ADR)(HCM)盘中下跌5.21%，截至22:20，报18.0美元/股，成交72.22万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：5月22日，和黄医药(US ADR)将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/26222040440599.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430232208","title":"呋喹替尼获欧洲药品管理局CHMP积极意见用于结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430232208","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2430232208?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:39","pubTimestamp":1714138740,"startTime":"0","endTime":"0","summary":"欧盟委员会在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时，将会把CHMP的积极意见纳入考虑。如果获得批准，呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体的选择性抑制剂。目前，欧盟转移性结直肠癌患者可用的治疗选择有限，导致治疗结果不佳。自呋喹替尼在中国上市以来，截至2023年年中已有超过8万名结直肠癌患者接受呋喹替尼治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4398604_ZH98604_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430708812","title":"Trinet Group, Inc.盘中异动 早盘大幅下跌13.76%报109.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430708812","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430708812?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:36","pubTimestamp":1714138563,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日21时36分，Trinet Group, Inc.股票出现波动，股价快速跳水13.76%。Trinet Group, Inc.股票所在的人员配备服务行业中，整体跌幅为0.36%。其相关个股中，Staffing 360 Solutions, Inc.、兼职精灵、BOSS直聘涨幅较大，Insperity, Inc.、Professional Diversity Network, Inc.、罗致恒富较为活跃，换手率分别为0.09%、0.05%、0.04%，振幅较大的相关个股有罗致恒富、Professional Diversity Network, Inc.、Trinet Group, Inc.，振幅分别为4.01%、2.87%、2.72%。Trinet Group, Inc.公司简介：Trinet Group Inc通过专业雇主组织，为中小型企业提供外包薪资和人力资本管理解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621360387b3f502&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621360387b3f502&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430227913","title":"和黄医药(00013)：武田获得欧洲药品管理局人用药品委员会积极意见支持呋喹替尼用于治疗经治转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430227913","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430227913?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:37","pubTimestamp":1714135046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，其合作伙伴武田取得欧洲药品管理局人用药品委员会建议批准呋喹替尼用于治疗经治的成人转移性结直肠癌患者。欧盟委员会在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时，将会把CHMP的积极意见纳入考量。如果获得批准，呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体的选择性抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112266.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430828187","title":"和黄医药(US ADR)上涨2.06%，报18.79美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430828187","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430828187?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:02","pubTimestamp":1714053747,"startTime":"0","endTime":"0","summary":"4月25日，和黄医药(US ADR)(HCM)盘中上涨2.06%，截至22:02，报18.79美元/股，成交24.75万美元。财务数据显示，截至2023年12月31日，和黄医药(US ADR)收入总额8.38亿美元，同比增长96.52%；归母净利润1.01亿美元，同比增长127.93%。大事提醒：5月22日，和黄医药(US ADR)将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25220240414697.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430627443","title":"和黄医药(00013)上涨5.12%，报30.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430627443","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430627443?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:10","pubTimestamp":1714014609,"startTime":"0","endTime":"0","summary":"4月25日，和黄医药(00013)盘中上涨5.12%，截至11:10，报30.8元/股，成交7740.05万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报，和黄医药营业总收入59.35亿元、净利润7.14亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/25111040400554.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443743","title":"和黄医药(00013)股价上升5.119%，现价港币$30.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443743","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430443743?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:09","pubTimestamp":1714014540,"startTime":"0","endTime":"0","summary":"[上升股]和黄医药(00013) 股价在上午11:09比前收市价上升5.119%，现股价为港币$30.8。至目前为止，今日最高价为$30.8，而最低价为$28.95。总成交量为251.7万股，总成交金额为港币$7.572千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404252162/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2430164414","title":"南向资金4月24日净买入和黄医药73.04万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430164414","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430164414?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:31","pubTimestamp":1714008669,"startTime":"0","endTime":"0","summary":"4月24日, 南向资金增持和黄医药73.04万股，连续3日增持。截止当日收盘，港股通共持有和黄医药15261.28万股，占流通股17.51%。港股通增持金额前五个股分别为腾讯控股、中国银行、中国财险、中国石油化工股份、中国移动。和黄医药近5个交易日上涨10.36%，港股通累计增持100.21万股；近20个交易日上涨12.05%，港股通累计减持73.45万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042509435487acf705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042509435487acf705&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429216942","title":"和黄医药：呋喹替尼美国上市两个月销售额达1510万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429216942","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429216942?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:01","pubTimestamp":1713859305,"startTime":"0","endTime":"0","summary":"快讯正文和黄医药午后股价急升5.39%，触及每股28.35港元截至发稿，和黄医药成交金额高达1.03亿港元。平安证券发布分析报告，指出该公司核心产品销售额实现迅猛增势，其拳头产品呋喹替尼在美国市场表现尤为抢眼。作为美国十年来首个获批治疗转移性结直肠癌的新药，呋喹替尼于2023年11月正式登陆美国市场。令人瞩目的是，上市短短两个月，其在美国市场的销售额迅速攀升至1510万美元，增长势头强劲。下载和讯APP查看快讯，体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231728538b49fdc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231728538b49fdc9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429156706","title":"港股异动 | 和黄医药(00013)午后涨近7% 呋喹替尼上市后放量迅速 多款重磅产品大适应症有望获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2429156706","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429156706?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:51","pubTimestamp":1713855096,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药(00013)午后涨近7%，截至发稿，涨6.13%，报28.55港元，成交额9464.06万港元。平安证券指出，公司核心产品销售额保持较快增长，呋喹替尼在美国于2023年11月上市，是美国十多年来首个获批用于治疗转移性结直肠癌的创新靶向疗法，上市仅两个月，美国市场销售额已高达1510万美元，放量迅速。此外，公司多款重磅产品大适应症有望于24年获批或申报NDA，有望不断催化公司价值提升。该行表示，考虑到公司上市产品适应症仍在拓展，同时公司在研管线丰富，管线估值有望进一步提升，维持“推荐”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107417.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0481},{"period":"1month","weight":0.2115},{"period":"3month","weight":0.4671},{"period":"6month","weight":0.0164},{"period":"1year","weight":0.2442},{"period":"ytd","weight":0.0944}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":-0.0036},{"period":"3month","weight":0.0457},{"period":"6month","weight":0.1814},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.0868}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司（原名：和黄中国医药科技有限公司）是一家主要从事药品制造及销售的投资控股公司。连同其附属公司，该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法，包括涵盖药物发现、开发、生产及监管职能的研发活动，以及支持研发业务的行政活动，还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.04629},{"month":2,"riseRate":0.375,"avgChangeRate":-0.008286},{"month":3,"riseRate":0.375,"avgChangeRate":-0.005299},{"month":4,"riseRate":0.555556,"avgChangeRate":0.042359},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.062401},{"month":6,"riseRate":0.75,"avgChangeRate":0.095866},{"month":7,"riseRate":0.5,"avgChangeRate":0.026735},{"month":8,"riseRate":0.5,"avgChangeRate":0.035365},{"month":9,"riseRate":0.375,"avgChangeRate":-0.043105},{"month":10,"riseRate":0.625,"avgChangeRate":0.00878},{"month":11,"riseRate":0.875,"avgChangeRate":0.147113},{"month":12,"riseRate":0.625,"avgChangeRate":0.007065}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况